McKesson Again Boosts Outlook After 2Q Revenue Jumps 10%

Dow Jones

11/06

By Paul Ziobro

McKesson again raised its adjusted profit outlook for the year after revenue rose 10% in the second quarter, boosted by higher prescription volumes and growth in distribution of oncology and multispecialty products.

The pharmaceutical distributor on Wednesday reported a profit of $1.11 billion, or $8.92 a share, compared with $241 million, or $1.87 a share, a year ago.

Adjusted earnings were $9.86 a share. Analysts polled by FactSet expected $9.03 a share.

Revenue rose about 10% to $103.15 billion, short of analyst estimates for $104.14 billion. The company said growth was led by its North American pharmaceutical segment, where it logged more prescription volumes. Acquisitions in its Oncology and Multispecialty segment also provided a boost.

The company said its bottom-line boost came from operational growth across its businesses, including contributions from acquisitions, the sale of an investment and market decisions within the U.S. Oncology Network, among other items.

McKesson now expects adjusted per-share earnings between $38.35 and $38.85, compared to its prior view of $38.05 to $38.55.

Write to Paul Ziobro at paul.ziobro@wsj.com

(END) Dow Jones Newswires

November 05, 2025 16:56 ET (21:56 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581001117"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581001117\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581001117?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 05:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581001117","market":"sh","top_or_hot":-1,"title":"McKesson Again Boosts Outlook After 2Q Revenue Jumps 10%","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Paul Ziobro \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  McKesson again raised its adjusted profit outlook for the year after revenue rose 10% in the second quarter, boosted by higher prescription volumes and growth in distribution of oncology and multispecialty products. \n</p>\n<p>\n  The pharmaceutical distributor on Wednesday reported a profit of $1.11 billion, or $8.92 a share, compared with $241 million, or $1.87 a share, a year ago. \n</p>\n<p>\n  Adjusted earnings were $9.86 a share. Analysts polled by FactSet expected $9.03 a share. \n</p>\n<p>\n  Revenue rose about 10% to $103.15 billion, short of analyst estimates for $104.14 billion. The company said growth was led by its <a href=\"https://laohu8.com/S/FNCSF\">North American</a> pharmaceutical segment, where it logged more prescription volumes. Acquisitions in its Oncology and Multispecialty segment also provided a boost. \n</p>\n<p>\n  The company said its bottom-line boost came from operational growth across its businesses, including contributions from acquisitions, the sale of an investment and market decisions within the U.S. Oncology Network, among other items. \n</p>\n<p>\n  McKesson now expects adjusted per-share earnings between $38.35 and $38.85, compared to its prior view of $38.05 to $38.55. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 05, 2025 16:56 ET (21:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>McKesson Again Boosts Outlook After 2Q Revenue Jumps 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMcKesson Again Boosts Outlook After 2Q Revenue Jumps 10%\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-11-06 05:56</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Paul Ziobro \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  McKesson again raised its adjusted profit outlook for the year after revenue rose 10% in the second quarter, boosted by higher prescription volumes and growth in distribution of oncology and multispecialty products. \n</p>\n<p>\n  The pharmaceutical distributor on Wednesday reported a profit of $1.11 billion, or $8.92 a share, compared with $241 million, or $1.87 a share, a year ago. \n</p>\n<p>\n  Adjusted earnings were $9.86 a share. Analysts polled by FactSet expected $9.03 a share. \n</p>\n<p>\n  Revenue rose about 10% to $103.15 billion, short of analyst estimates for $104.14 billion. The company said growth was led by its <a href=\"https://laohu8.com/S/FNCSF\">North American</a> pharmaceutical segment, where it logged more prescription volumes. Acquisitions in its Oncology and Multispecialty segment also provided a boost. \n</p>\n<p>\n  The company said its bottom-line boost came from operational growth across its businesses, including contributions from acquisitions, the sale of an investment and market decisions within the U.S. Oncology Network, among other items. \n</p>\n<p>\n  McKesson now expects adjusted per-share earnings between $38.35 and $38.85, compared to its prior view of $38.05 to $38.55. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 05, 2025 16:56 ET (21:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MCK","symbol_name":"麥克森藥物批發","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2581001117","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581001117","pubTimestamp":1762379760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"McKesson again raised its adjusted profit outlook for the year after revenue rose 10% in the second quarter, boosted by higher prescription volumes and growth in distribution of oncology and multispecialty products.The pharmaceutical distributor on Wednesday reported a profit of $1.11 billion, or $8.92 a share, compared with $241 million, or $1.87 a share, a year ago.Adjusted earnings were $9.86 a share. Analysts polled by FactSet expected $9.03 a share.Revenue rose about 10% to $103.15 billion, short of analyst estimates for $104.14 billion. The company said growth was led by its North American pharmaceutical segment, where it logged more prescription volumes. Acquisitions in its Oncology and Multispecialty segment also provided a boost.The company said its bottom-line boost came from operational growth across its businesses, including contributions from acquisitions, the sale of an investment and market decisions within the U.S. Oncology Network, among other items.McKesson now expect","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MCK":"麦克森药物批发"},"translate_title":"McKesson在第二季度收入增长10%后再次上调前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MCK":1.5},"content_text":"By Paul Ziobro \n\n\n \n\n\n  McKesson again raised its adjusted profit outlook for the year after revenue rose 10% in the second quarter, boosted by higher prescription volumes and growth in distribution of oncology and multispecialty products. \n\n\n  The pharmaceutical distributor on Wednesday reported a profit of $1.11 billion, or $8.92 a share, compared with $241 million, or $1.87 a share, a year ago. \n\n\n  Adjusted earnings were $9.86 a share. Analysts polled by FactSet expected $9.03 a share. \n\n\n  Revenue rose about 10% to $103.15 billion, short of analyst estimates for $104.14 billion. The company said growth was led by its North American pharmaceutical segment, where it logged more prescription volumes. Acquisitions in its Oncology and Multispecialty segment also provided a boost. \n\n\n  The company said its bottom-line boost came from operational growth across its businesses, including contributions from acquisitions, the sale of an investment and market decisions within the U.S. Oncology Network, among other items. \n\n\n  McKesson now expects adjusted per-share earnings between $38.35 and $38.85, compared to its prior view of $38.05 to $38.55. \n\n\n \n\n\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 16:56 ET (21:56 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}